Literature DB >> 29773065

Copper-Catalyzed Azide-Alkyne Cycloaddition (CuAAC)-Mediated Macrocyclization of Peptides: Impact on Conformation and Biological Activity.

Chiara Testa1,2,3, Anna Maria Papini1,2,3, Michael Chorev4, Paolo Rovero1,5.   

Abstract

The long-lasting impetus to design novel modes of macrocyclization, and their implementation into a wide range of bioactive peptides, originates from their contributions to the restriction of conformational space and the stabilization of preferential bioactive conformations that support higher efficacy and binding affinity to cognate macromolecular targets, improved specificity and lowering susceptibility to enzymatic degradation processes. Introducing CuI-catalyzed azide-alkyne cycloaddition (CuAAC), a prototypical click reaction, to the field of peptide sciences as a bio-orthogonal reaction that generates a disubstituted-[1,2,3]triazol-1-yl moiety as a pseudopeptidic bond that is peptidomimetic in nature, paved the way to its widespread application as a new and promising mode of macrocyclization. This review presents the state-of-art of CuAAC-mediated macrocyclization as it applies to an expansive range of bioactive peptides and explores the relationship among the structural diversity of CuAACmediated cyclizations, biological activities and conformations. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Copper-catalyzed; CuAAC-mediated; azide-alkyne; macrocyclization; peptidomimetics; pseudopeptides.

Mesh:

Substances:

Year:  2018        PMID: 29773065     DOI: 10.2174/1568026618666180518095755

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  2 in total

1.  Synthetic short-chain peptide analogues of H1 relaxin lack affinity for the RXFP1 receptor and relaxin-like bioactivity. Clues to a better understanding of relaxin agonist design.

Authors:  Annunziata D'Ercole; Silvia Nistri; Lorenzo Pacini; Alfonso Carotenuto; Federica Santoro; Anna Maria Papini; Ross A D Bathgate; Daniele Bani; Paolo Rovero
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

Review 2.  Triazole-Modified Peptidomimetics: An Opportunity for Drug Discovery and Development.

Authors:  Agnieszka Staśkiewicz; Patrycja Ledwoń; Paolo Rovero; Anna Maria Papini; Rafal Latajka
Journal:  Front Chem       Date:  2021-05-20       Impact factor: 5.221

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.